These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1794222)

  • 1. Calcium-channel blockers for treatment of diabetic nephropathy.
    Murray KM
    Clin Pharm; 1991 Nov; 10(11):862-5. PubMed ID: 1794222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
    O'Donnell MJ; Rowe BR; Lawson N; Horton A; Gyde OH; Barnett AH
    J Hum Hypertens; 1993 Aug; 7(4):333-9. PubMed ID: 8410924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approach to the treatment of diabetic nephropathy.
    Burke JM
    Pharm Pract Manag Q; 1997 Jul; 17(2):26-35. PubMed ID: 10168175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy.
    Smith AC; Toto R; Bakris GL
    Kidney Int; 1998 Sep; 54(3):889-96. PubMed ID: 9734613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
    Moriyama T; Oka K; Ueda H; Imai E
    Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical studies on chronic diabetic nephropathy and recent data concerning prevention of risks of nephropathy and cardiovascular diseases].
    Esnault V
    Nephrol Ther; 2006 May; 2 Suppl 3():S193-6. PubMed ID: 17370850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glomerular dysfunction in diabetic nephropathy.
    Zucchelli P; Zuccalà A; Sturani A
    Postgrad Med J; 1988; 64 Suppl 3():22-30; discussion 48-9. PubMed ID: 3074295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The renin angiotensin system in diabetes mellitus. A physiological and therapeutic study.
    Björck S
    Scand J Urol Nephrol Suppl; 1990; 126():1-51. PubMed ID: 2194280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Converting enzyme inhibitors and calcium antagonists in the long-term treatment of hypertension in chronic renal failure.
    Lenz T; August P
    Wien Klin Wochenschr; 1990 May; 102(11):315-9. PubMed ID: 2195780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of calcium channel blocker therapy in diabetes mellitus.
    Savage S; Miller LA; Schrier RW
    J Cardiovasc Pharmacol; 1991; 18 Suppl 1():S19-24. PubMed ID: 1723450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nondihydropyridine Calcium Channel Blockers for the Treatment of Proteinuria: A Review of the Literature.
    Steuber TD; Lee J; Holloway A; Andrus MR
    Ann Pharmacother; 2019 Oct; 53(10):1050-1059. PubMed ID: 30966785
    [No Abstract]   [Full Text] [Related]  

  • 17. The antiproteinuric effect of antihypertensive agents in diabetic nephropathy.
    Gansevoort RT; Apperloo AJ; Heeg JE; de Jong PE; de Zeeuw D
    Arch Intern Med; 1992 Oct; 152(10):2137-9. PubMed ID: 1417388
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group.
    Jerums G; Allen TJ; Tsalamandris C; Cooper ME
    Kidney Int; 1992 Apr; 41(4):904-11. PubMed ID: 1513112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal long-term effects of calcium antagonist treatment in patients with diabetes mellitus.
    Jungmann E; Usadel KH
    Clin Investig; 1992 Oct; 70(10):942-8. PubMed ID: 1450619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium antagonists and the diabetic hypertensive patient.
    Parving HH; Rossing P
    Am J Kidney Dis; 1993 Jun; 21(6 Suppl 3):47-52. PubMed ID: 8503435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.